Background The advent of short-course, curative treatment with direct-acting antivirals (DAA)
has given promise for the global elimination of hepatitis C virus (HCV) infections by 2030 …

Background Real-world data are scarce about the effectiveness and safety of
sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for retreating East Asian patients with …

Despite tremendous advances in the management of HCV, including the availability of a
curative treatment, an estimated 57 million people worldwide are living with chronic HCV. 1 …

Background: Direct-acting antiviral (DAA) treatment discontinuation may negatively impact
HCV elimination efforts. In Australia, DAA therapy is pharmacy dispensed, generally in 4 …

Hepatitis C virus (HCV) causes substantial morbidity and mortality, particularly among
people who inject drugs (PWID). While elimination of HCV as a public health problem may …

Background & Aims Population-level uptake of direct-acting antiviral (DAA) treatment for
hepatitis C virus (HCV) infection, including retreatment, can be estimated through …

Introduction The first direct-acting antiviral (DAA) therapies for chronic hepatitis C virus
(HCV) infection were reimbursed via Australia's Pharmaceutical Benefits Scheme (PBS) in …

Abstract Background & Aims The use of direct acting antiviral agents (DAAs) in patients with
chronic HCV genotype (GT) 3a infection results in sustained virologic response (SVR) rates …

Background: Direct-acting antiviral (DAA) treatment is being scaled up to eliminate hepatitis
C virus (HCV) as a major public health threat. Aims: The aim of this research was to assess …

IMPLICATIONS OF REINFECTION FOR HEPATITIS C ELIMINATION AMONG PEOPLE
WHO INJECT DRUGS by KYRA HOLLISTER GRANTZ A dissertation su Page 1 …